Bradley C Leibovich

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi Outcomes following partial nephrectomy by tumor size
    Paul L Crispen
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Urol 180:1912-7. 2008
  2. ncbi Surgical management of renal cell carcinoma
    Bradley C Leibovich
    Department of Urology, Mayo Medical School, Mayo Clinic, Rochester, MN 55905, USA
    Semin Oncol 33:552-62. 2006
  3. ncbi Cancer specific survival for patients with pT3 renal cell carcinoma-can the 2002 primary tumor classification be improved?
    Bradley C Leibovich
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota 55905, USA
    J Urol 173:716-9. 2005
  4. ncbi Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy
    Bradley C Leibovich
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota 55905, USA
    J Urol 171:1066-70. 2004
  5. ncbi Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials
    Bradley C Leibovich
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 97:1663-71. 2003
  6. ncbi Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma
    Bradley C Leibovich
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Urol 183:1309-15. 2010
  7. ncbi A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials
    Bradley C Leibovich
    Department of Urology, Mayo Medical School, Rochester, Minnesota, USA
    J Urol 174:1759-63; discussion 1763. 2005
  8. ncbi Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma
    R Houston Thompson
    Department of Urology, Mayo Medical School, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 104:2084-91. 2005
  9. ncbi Dynamic prediction of metastases after radical prostatectomy for prostate cancer
    Brant A Inman
    Division of Urology, Duke University Medical Center, Durham, NC, USA
    BJU Int 108:1762-8. 2011
  10. ncbi Routine adrenalectomy in patients with locally advanced renal cell cancer does not offer oncologic benefit and places a significant portion of patients at risk for an asynchronous metastasis in a solitary adrenal gland
    Christopher J Weight
    Department of Urology, Mayo Clinic, Rochester, MN 55905, USA
    Eur Urol 60:458-64. 2011

Detail Information

Publications98

  1. ncbi Outcomes following partial nephrectomy by tumor size
    Paul L Crispen
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Urol 180:1912-7. 2008
    ..We established long-term survival in patients following partial nephrectomy according to tumor size...
  2. ncbi Surgical management of renal cell carcinoma
    Bradley C Leibovich
    Department of Urology, Mayo Medical School, Mayo Clinic, Rochester, MN 55905, USA
    Semin Oncol 33:552-62. 2006
    ..Herein, we discuss the role of surgery for the management of localized and metastatic RCC...
  3. ncbi Cancer specific survival for patients with pT3 renal cell carcinoma-can the 2002 primary tumor classification be improved?
    Bradley C Leibovich
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota 55905, USA
    J Urol 173:716-9. 2005
    ..We evaluated the association of tumor thrombus level and fat invasion with outcome to determine if further subclassification would improve the prognostic accuracy of the current classification...
  4. ncbi Nephron sparing surgery for appropriately selected renal cell carcinoma between 4 and 7 cm results in outcome similar to radical nephrectomy
    Bradley C Leibovich
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota 55905, USA
    J Urol 171:1066-70. 2004
    ..We compared outcomes between patients treated with nephron sparing surgery (NSS) without imperative indications for renal preservation and radical nephrectomy (RN) for 4 to 7 cm renal cell carcinoma (RCC)...
  5. ncbi Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials
    Bradley C Leibovich
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 97:1663-71. 2003
    ....
  6. ncbi Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma
    Bradley C Leibovich
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Urol 183:1309-15. 2010
    ..We examined the significance of histological subtype on progression to distant metastasis and cancer specific death after nephrectomy...
  7. ncbi A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials
    Bradley C Leibovich
    Department of Urology, Mayo Medical School, Rochester, Minnesota, USA
    J Urol 174:1759-63; discussion 1763. 2005
    ..We developed a clinically useful scoring algorithm to predict cancer specific survival for patients with clear cell metastatic renal cell carcinoma (RCC)...
  8. ncbi Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma
    R Houston Thompson
    Department of Urology, Mayo Medical School, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 104:2084-91. 2005
    ..The authors surmised that B7-H1 blockade may augment current immunotherapy, including patients treated for metastases after cytoreductive nephrectomy...
  9. ncbi Dynamic prediction of metastases after radical prostatectomy for prostate cancer
    Brant A Inman
    Division of Urology, Duke University Medical Center, Durham, NC, USA
    BJU Int 108:1762-8. 2011
    ..The net result is a dynamic tool that renders clinically relevant predictions that change as the patient's clinical status changes throughout the postoperative course...
  10. ncbi Routine adrenalectomy in patients with locally advanced renal cell cancer does not offer oncologic benefit and places a significant portion of patients at risk for an asynchronous metastasis in a solitary adrenal gland
    Christopher J Weight
    Department of Urology, Mayo Clinic, Rochester, MN 55905, USA
    Eur Urol 60:458-64. 2011
    ..The indications for the removal of the ipsilateral adrenal gland in patients with renal cell carcinoma (RCC) and the long-term outcomes have not been well studied...
  11. ncbi B7-H1 glycoprotein blockade: a novel strategy to enhance immunotherapy in patients with renal cell carcinoma
    R Houston Thompson
    Department of Urology, Mayo Medical School, Mayo Clinic, Rochester, Minnesota 55905, USA
    Urology 66:10-4. 2005
    ..35-9.15; P = 0.010). Tumor-associated B7-H1 expression is significantly associated with poor prognosis among patients with clear-cell RCC. Manipulation of B7-H1 with therapeutic intent remains a realistic and viable therapeutic option...
  12. ncbi Obesity and survival after radical prostatectomy: A 10-year prospective cohort study
    Sameer A Siddiqui
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 107:521-9. 2006
    ..However, after prostatectomy, BMI does not appear to be an independent predictor of recurrence or survival...
  13. ncbi Reclassification of patients with pT3 and pT4 renal cell carcinoma improves prognostic accuracy
    R Houston Thompson
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 104:53-60. 2005
    ..61 vs. 0.55, respectively). CONCLUSIONS: Direct adrenal invasion from RCC should be reclassified as pT4. In addition, the proposed reclassification for patients with pT3 RCC improved prognostic accuracy...
  14. ncbi Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma
    Paul L Crispen
    Department of Urology, Mayo Clinic, Rochester, Minnesota, USA
    Clin Cancer Res 14:5150-7. 2008
    ..As such, we evaluated the association of B7-H3 expression with clinicopathologic outcomes in patients treated for ccRCC...
  15. ncbi Trends in distribution and prognostic significance of Gleason grades on radical retropubic prostatectomy specimens between 1989 and 2001
    Shomik Sengupta
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 106:2630-5. 2006
    ..A chronological change in pathologic grading classification is suggested by evolving prognostic implications, which must be accounted for when comparing outcomes from different eras...
  16. ncbi After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer
    Shomik Sengupta
    Department of Urology, Mayo Clinic, Rochester, MN 55905, USA
    BJU Int 101:170-4. 2008
    ....
  17. ncbi Survivin and b7-h1 are collaborative predictors of survival and represent potential therapeutic targets for patients with renal cell carcinoma
    Amy E Krambeck
    Department of Urology, Mayo Medical School, Mayo Clinic, Rochester, MN 55905, USA
    Clin Cancer Res 13:1749-56. 2007
    ..Herein, we examine the clinical effect of ccRCC combined expression of both survivin and B7-H1...
  18. ncbi Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials
    Bradley C Leibovich
    University of California-Los Angeles Kidney Cancer Program, Department of Urology, University of California-Los Angeles School of Medicine, Los Angeles, California 90095-1738, USA
    Cancer 98:2566-75. 2003
    ..The authors present a scoring algorithm based on these features that can be used to predict survival in patients who present with metastatic RCC and to stratify such patients for prospective clinical trials...
  19. ncbi Renal function after partial nephrectomy: effect of warm ischemia relative to quantity and quality of preserved kidney
    R Houston Thompson
    Mayo Medical School and Mayo Clinic, Rochester, Minnesota, USA
    Urology 79:356-60. 2012
    ..To evaluate the effects of warm ischemia time (WIT) and quantity and quality of kidney preserved on renal functional recovery after partial nephrectomy (PN). The effect of WIT relative to these other parameters has recently been challenged...
  20. ncbi Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma
    Bradley C Leibovich
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 25:4757-64. 2007
    ..We attempted to validate the prognostic utility of CAIX expression using a large cohort of ccRCC patients with long-term follow-up...
  21. ncbi High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma
    Alexander S Parker
    Department of Urology, Mayo Clinic College of Medicine, Jacksonville, Florida, USA
    Cancer 107:37-45. 2006
    ..What remained in question was whether survivin expression at the protein level is an independent predictor of disease progression and cancer-specific survival...
  22. ncbi Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up
    R Houston Thompson
    Department of Urology, Mayo Medical School, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Cancer Res 66:3381-5. 2006
    ..RCC patients with tumor B7-H1 are at significant risk of rapid cancer progression and accelerated rates of mortality. B7-H1 may function as a key determinant in RCC, abrogating immune responses directed against this immunogenic tumor...
  23. ncbi Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness
    Shomik Sengupta
    Department of Urology, Mayo Medical School and Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Cancer 104:511-20. 2005
    ..90; P < 0.001). CONCLUSIONS: Histologic coagulative tumor necrosis is an independent predictor of outcome for clear cell and chromophobe RCC, and it should be routinely reported and used in clinical assessment...
  24. ncbi Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma
    Alexander S Parker
    Department of Urology, Mayo Medical School, Jacksonville, Florida, USA
    Cancer 115:2092-103. 2009
    ..In the current study, they described the creation of a scoring system based on this panel of biomarkers that can be used in tandem with existing clinicopathologic features and algorithms to improve ccRCC outcome prediction...
  25. ncbi Mononuclear cell infiltration in clear-cell renal cell carcinoma independently predicts patient survival
    W Scott Webster
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 107:46-53. 2006
    ..61; P = .028). CONCLUSIONS: Mononuclear cell infiltration is associated with death from RCC even after multivariate adjustment. Routine documentation of mononuclear cell infiltration is recommended during the pathologic assessment of RCC...
  26. ncbi Is the GPSM scoring algorithm for patients with prostate cancer valid in the contemporary era?
    R Houston Thompson
    Department of Urology and Division of Biostatistics, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    J Urol 178:459-63; discussion 463. 2007
    ..It was developed from patients who underwent radical retropubic prostatectomy from 1990 to 1993. We investigated the predictive ability of GPSM in the contemporary era...
  27. ncbi Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort
    Igor Frank
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota, USA
    J Urol 173:1889-92. 2005
    ..In the current study we evaluated the 2002 primary tumor classification and compared its predictive ability with that of the 1997 classification...
  28. ncbi Surgical treatment of renal cell carcinoma in the immunocompromised transplant patient
    Matthew K Tollefson
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota 55905, USA
    Urology 75:1373-7. 2010
    ..To determine whether iatrogenic immunosuppression used after transplantation infers a poor prognosis of renal cell carcinoma (RCC) as natural negative immune regulators have been associated with decreased cancer-specific survival from RCC...
  29. ncbi Lymph node dissection at the time of radical nephrectomy for high-risk clear cell renal cell carcinoma: indications and recommendations for surgical templates
    Paul L Crispen
    Department of Urology, Mayo Clinic, Rochester, MN 55905, USA
    Eur Urol 59:18-23. 2011
    ..Observational studies suggest a proportion of patients with lymph node metastases will benefit from lymph node dissection (LND) at the time of nephrectomy for clear cell renal cell carcinoma (RCC)...
  30. ncbi Is renal sinus fat invasion the same as perinephric fat invasion for pT3a renal cell carcinoma?
    R Houston Thompson
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota 55905, USA
    J Urol 174:1218-21. 2005
    ..We investigated the prognostic significance of each of these pathological features using a cohort of pT3a patients...
  31. ncbi Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a preoperative serum prostate-specific antigen level > or =50 ng/mL
    Brant A Inman
    Department of Urology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cancer 113:1544-51. 2008
    ..The authors evaluated the long-term outcomes of men with prostate cancer and very high (> or =50 ng/mL) preoperative serum prostate-specific antigen (PSA) values that were treated with radical prostatectomy...
  32. ncbi B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival
    Amy E Krambeck
    Department of Urology, Mayo Medical School, Mayo Clinic, Rochester, MN 55905, USA
    Proc Natl Acad Sci U S A 103:10391-6. 2006
    ..Last, we demonstrate that patients with RCC tumors expressing both B7-H4 and B7-H1 are at an even greater risk of death from RCC...
  33. ncbi External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma
    Nathan E Hoffmann
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 112:1471-9. 2008
    ....
  34. ncbi Ki-67 and coagulative tumor necrosis are independent predictors of poor outcome for patients with clear cell renal cell carcinoma and not surrogates for each other
    Matthew K Tollefson
    Department of Urology, Mayo Clinic and Mayo Medical School, Rochester, MN 55905, USA
    Cancer 110:783-90. 2007
    ..Thus, the goal was to directly test whether Ki-67 and necrosis convey similar or distinct information for the prognostic assessment of ccRCC...
  35. ncbi Patients with pT1 renal cell carcinoma who die from disease after nephrectomy may have unrecognized renal sinus fat invasion
    Robert Houston Thompson
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, MN 55905, USA
    Am J Surg Pathol 31:1089-93. 2007
    ..Appropriate assessment of nephrectomy specimens should include proper sampling of the renal sinus even for seemingly localized tumors...
  36. ncbi A multifactorial postoperative surveillance model for patients with surgically treated clear cell renal cell carcinoma
    Igor Frank
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota, USA
    J Urol 170:2225-32. 2003
    ..CONCLUSIONS: We present scoring algorithms based on multivariately significant predictors of site specific recurrence that can be used to tailor postoperative surveillance to the individual patient...
  37. ncbi Comparative effectiveness for survival and renal function of partial and radical nephrectomy for localized renal tumors: a systematic review and meta-analysis
    Simon P Kim
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Urol 188:51-7. 2012
    ..We performed a systematic review and meta-analysis of partial vs radical nephrectomy for localized renal tumors, considering all cause and cancer specific mortality, and severe chronic kidney disease...
  38. ncbi Increasing prostate specific antigen following radical prostatectomy and adjuvant hormonal therapy: doubling time predicts survival
    Shomik Sengupta
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Urol 175:1684-90; discussion 1690. 2006
    ..Nodal status, cancer grade and PSADT are predictive of sRFS and CSS, and may be a useful means of selecting patients for future adjuvant therapy trials...
  39. ncbi Percutaneous renal cryoablation: local control at mean 26 months of followup
    Thomas D Atwell
    Department of Radiology, Mayo Clinic, Rochester, Minnesota 55902, USA
    J Urol 184:1291-5. 2010
    ..We retrospectively determined the efficacy of percutaneous renal cryoablation based on a mean followup of more than 2 years...
  40. ncbi Treatment of patients with small renal masses: a survey of the American Urological Association
    Rodney H Breau
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55901, USA
    J Urol 185:407-13. 2011
    ..We surveyed American Urological Association members to determine factors that influence the treatment of patients with small renal masses...
  41. ncbi A protocol for performing extended lymph node dissection using primary tumor pathological features for patients treated with radical nephrectomy for clear cell renal cell carcinoma
    Michael L Blute
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Urol 172:465-9. 2004
    ....
  42. ncbi Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy
    Matthew K Tollefson
    Department of Urology, College of Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:422-7. 2007
    ....
  43. ncbi Percutaneous cryoablation of renal masses >or=3 cm: efficacy and safety in treatment of 108 patients
    Grant D Schmit
    Department of Radiology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Endourol 24:1255-62. 2010
    ..To evaluate our single institution experience with percutaneous cryoablation of renal masses >or=3 cm in diameter for complications and short-term outcomes...
  44. ncbi Should direct ipsilateral adrenal invasion from renal cell carcinoma be classified as pT3a?
    R Houston Thompson
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota 55905, USA
    J Urol 173:918-21. 2005
    ..In the current study we evaluated the association of direct ipsilateral adrenal invasion with outcome to determine if reclassification of these tumors as pT4 would improve the accuracy of the current tumor classification...
  45. ncbi The preoperative erythrocyte sedimentation rate is an independent prognostic factor in renal cell carcinoma
    Shomik Sengupta
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 106:304-12. 2006
    ..For patients with clear cell RCC, the ESR provided useful information above and beyond traditional prognostic algorithms, and it may be valuable for preoperative prognostication...
  46. ncbi Assessment of the pathologic inclusion criteria from contemporary adjuvant clinical trials for predicting disease progression after nephrectomy for renal cell carcinoma
    Simon P Kim
    Department of Urology, Mayo Clinic, Rochester, MN, USA
    Cancer 118:4412-20. 2012
    ..The objective of this study was to evaluate the accuracy of the pathologic inclusion criteria from all contemporary adjuvant trials in predicting disease progression (DP) for renal cell carcinoma (RCC)...
  47. ncbi Complications following 573 percutaneous renal radiofrequency and cryoablation procedures
    Thomas D Atwell
    Department of Radiology, Mayo Clinic, 200 First St SW, Rochester, MN 55902, USA
    J Vasc Interv Radiol 23:48-54. 2012
    ..To review complications related to percutaneous renal tumor ablation...
  48. ncbi Metastatic potential of a renal mass according to original tumour size at presentation
    Eric C Umbreit
    Department of Urology, Mayo Clinic, Rochester, MN, USA
    BJU Int 109:190-4; discussion 194. 2012
    ..To determine the metastatic potential of renal masses based on original tumour size...
  49. ncbi Results of inferior vena caval interruption by greenfield filter, ligation or resection during radical nephrectomy and tumor thrombectomy
    Michael L Blute
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota, USA
    J Urol 178:440-5; discussion 444. 2007
    ..We describe the indications, technique, complications and outcomes of vena caval interruption during nephrectomy with tumor thrombectomy...
  50. ncbi Every minute counts when the renal hilum is clamped during partial nephrectomy
    R Houston Thompson
    Department of Urology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Eur Urol 58:340-5. 2010
    ..The safe duration of warm ischemia during partial nephrectomy remains controversial...
  51. ncbi Association of abnormal preoperative laboratory values with survival after radical nephrectomy for clinically confined clear cell renal cell carcinoma
    James S Magera
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Urology 71:278-82. 2008
    ..To determine whether preoperative laboratory values are independently associated with death from clinically confined clear cell renal cell carcinoma (RCC) after radical nephrectomy...
  52. ncbi Surgical management, complications, and outcome of radical nephrectomy with inferior vena cava tumor thrombectomy facilitated by vascular bypass
    Candace F Granberg
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota 55905, USA
    Urology 72:148-52. 2008
    ..The indications and results for venovenous bypass (VVB) versus cardiopulmonary bypass (CPB) were reviewed as well...
  53. ncbi Predicting disease progression after nephrectomy for localized renal cell carcinoma: the utility of prognostic models and molecular biomarkers
    Paul L Crispen
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55902, USA
    Cancer 113:450-60. 2008
    ..As such, the authors review the current prognostic tools for predicting disease progression for localized RCC, and detail studies to date that have evaluated various biomarkers in this setting...
  54. ncbi Comparison of digital image analysis versus visual assessment to assess survivin expression as an independent predictor of survival for patients with clear cell renal cell carcinoma
    Alexander S Parker
    Department of Urology, Mayo Clinic College of Medicine, Jacksonville, FL 32224, USA
    Hum Pathol 39:1176-84. 2008
    ..Thus, visual assessment represents an economical, widely available, and reliable method to assess survivin as a predictor of clear cell renal cell carcinoma patient outcomes...
  55. ncbi Postoperative surveillance for renal cell carcinoma: a multifactorial histological subtype specific protocol
    Sameer A Siddiqui
    Department of Urology, Mayo Clinic, Rochester, MN, USA
    BJU Int 104:778-85. 2009
    ....
  56. ncbi T-cell co-regulatory molecule expression in renal angiomyolipoma and pulmonary lymphangioleiomyomatosis
    Stephen A Boorjian
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota 55905, USA
    Urology 74:1359-64. 2009
    ..AML is a highly vascular tumor that most frequently emanates from the kidney. Events leading to its pathogenesis remain enigmatic and understudied...
  57. ncbi Greater body mass index is associated with better pathologic features and improved outcome among patients treated surgically for clear cell renal cell carcinoma
    Alexander S Parker
    Department of Urology, Mayo Clinic Jacksonville, Jacksonville, Florida 32224, USA
    Urology 68:741-6. 2006
    ..CONCLUSIONS: BMI offers little additional prognostic information beyond the accepted prognostic features; however, the association of an increased BMI with a less-aggressive disease profile at presentation warrants further exploration...
  58. ncbi T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival
    Stephen A Boorjian
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Cancer Res 14:4800-8. 2008
    ..We evaluated expression of the T-cell coregulators B7-H1, B7-H3, and PD-1 in urothelial cell carcinoma (UCC) of the bladder...
  59. ncbi Clear cell renal cell carcinoma: gene expression analyses identify a potential signature for tumor aggressiveness
    Farhad Kosari
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Cancer Res 11:5128-39. 2005
    ..Our data also indicate that the gene expression alterations that result in aggressive behavior and metastatic potential can be identified in the primary tumor...
  60. ncbi Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy
    R Houston Thompson
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota, USA
    J Urol 179:468-71; discussion 472-3. 2008
    ..We reviewed our surgical experience with small renal tumors, comparing overall survival in patients treated with radical and partial nephrectomy...
  61. ncbi PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma
    R Houston Thompson
    Department of Urology, Mayo Medical School, Mayo Clinic, Rochester, MN 55905, USA
    Clin Cancer Res 13:1757-61. 2007
    ..Levels of immune cells expressing PD-1 (PD-1(+)) in clinical RCC tumors have not been evaluated. Thus, we tested whether immune cell PD-1 expression is observed within aggressive RCC tumors...
  62. ncbi Outcomes and clinicopathologic variables associated with late recurrence after nephrectomy for localized renal cell carcinoma
    Simon P Kim
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Urology 78:1101-6. 2011
    ..To characterize the incidence and clinicopathologic factors associated with late recurrence after surgical resection for renal cell carcinoma (RCC) because the recurrence patterns >5 years after nephrectomy have been poorly described...
  63. ncbi Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome
    John C Cheville
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Surg Pathol 28:435-41. 2004
    ..59; P = 0.010) and after adjusting for TNM stage, tumor size, and histologic tumor necrosis (risk ratio 1.46; P = 0.037)...
  64. ncbi Dynamic outcome prediction in patients with clear cell renal cell carcinoma treated with radical nephrectomy: the D-SSIGN score
    R Houston Thompson
    Department of Urology, Health Sciences Research, Mayo Medical School, Mayo Clinic, Rochester, Minnesota, USA
    J Urol 177:477-80. 2007
    ..We created a dynamic outcome prediction model for continual surveillance that accounts for the disease-free interval following surgery...
  65. ncbi Complications of contemporary open nephron sparing surgery: a single institution experience
    R Houston Thompson
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota 55905, USA
    J Urol 174:855-8. 2005
    ..We reviewed our experience with contemporary open NSS, comparing complication rates to those of historical controls and updating data for comparison with minimally invasive procedures...
  66. ncbi Impact of tumor size on the predictive ability of the pT3a primary tumor classification for renal cell carcinoma
    Sameer A Siddiqui
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Urol 177:59-62. 2007
    ..We investigated the association of perinephric and renal sinus fat invasion with death from renal cell carcinoma independent of tumor size...
  67. ncbi Tumor-infiltrating Foxp3-CD4+CD25+ T cells predict poor survival in renal cell carcinoma
    Sameer A Siddiqui
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Clin Cancer Res 13:2075-81. 2007
    ..We tested for the presence of putative Tregs within renal cell carcinoma (RCC) tumors...
  68. ncbi Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy
    Matthew H T Bui
    Department of Urology, University of California, Los Angeles, California 90095 1738, USA
    Clin Cancer Res 9:802-11. 2003
    ..To date, there are no molecular markers which can reliably predict RCC outcome. We investigated whether a novel kidney cancer marker, carbonic anhydrase IX (CAIX), is associated with progression and survival...
  69. ncbi Lymph node dissection in the management of renal cell carcinoma
    Bradley C Leibovich
    Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA
    Urol Clin North Am 35:673-8; viii. 2008
    ..This article examines the rationale for lymphadenectomy in the management of renal cell carcinoma and reviews the limited literature on the subject...
  70. ncbi Should there be a size limit for elective nephron-sparing surgery?
    Kent G Krejci
    Department of Urology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Curr Urol Rep 4:21-9. 2003
    ..Current data clearly support the use of elective NSS for localized solid renal masses under 4 cm in size...
  71. ncbi Surgical treatment of stage pT3b renal cell carcinoma in solitary kidneys: a case series
    Shomik Sengupta
    Urology Department, Mayo Clinic, Rochester, MN, USA
    BJU Int 96:54-7. 2005
    ..There was oncological success in a third of the patients. The treatment of these patients needs to be individualized, as alternatives to NSS (RN or observation) have obvious disadvantages...
  72. ncbi Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity?
    Ashraf A Mosharafa
    Department of Urology, Indiana University School of Medicine, Indianapolis, Indiana, USA
    J Urol 169:2126-8. 2003
    ..We examined the impact of seminomatous elements on the rate of complications and the need for additional intraoperative procedures in patients undergoing post-chemotherapy retroperitoneal lymph node dissection...
  73. ncbi How long is too long? The effect of the duration of anaesthesia on the incidence of non-urological complications after surgery
    Jonathan C Routh
    Department of Urology, Mayo Clinic, Rochester, MN 55905, USA
    BJU Int 102:301-4. 2008
    ....
  74. ncbi Radical retropubic prostatectomy in immunosuppressed transplant recipients
    R Houston Thompson
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota 55902, USA
    J Urol 179:1349-52; discussion 1352-3. 2008
    ..We reviewed our experience with radical retropubic prostatectomy in patients with solid organ transplants...
  75. ncbi The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus
    Michael L Blute
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    BJU Int 94:33-41. 2004
    ..To report the surgical management, complications and outcomes over three decades by tumour thrombus level for patients with renal cell carcinoma (RCC) and renal venous extension, as surgery is the most effective treatment...
  76. ncbi pT2 classification for renal cell carcinoma. Can its accuracy be improved?
    Igor Frank
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota 55905, USA
    J Urol 173:380-4. 2005
    ..In this study we determined whether a size cutoff point exists within pT2 tumors and whether such subclassification would further improve the accuracy of the current tumor classification...
  77. ncbi Applications of positron emission tomography imaging, intraoperative ultrasonography, magnetic resonance imaging, and angiography in the evaluation of renal masses
    R Houston Thompson
    Department of Urology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Curr Urol Rep 5:30-4. 2004
    ....
  78. ncbi History of urinary tract infection and risk of renal cell carcinoma
    Alexander S Parker
    Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA
    Am J Epidemiol 159:42-8. 2004
    ..Results suggest a positive association of UTI history with RCC development, with elevated risks most notable for males with a history of smoking...
  79. ncbi Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma
    Ken-ryu Han
    Department of Urology, University of California, Los Angeles, School of Medicine, Los Angeles, CA 90095, USA
    Urology 61:314-9. 2003
    ..Survival in patients with disease limited to the lung was similar to that of patients whose disease was limited to bone...
  80. ncbi Adjuvant external radiation therapy following radical prostatectomy for node-negative prostate cancer
    Brian J Davis
    Division of Radiation Oncology and Department of Urology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Curr Opin Urol 13:117-22. 2003
    ..The use of adjuvant radiation therapy following prostatectomy is commonplace. The purpose of this review is to summarize completed and ongoing clinical trials and to review recent relevant studies and debates related to this subject...
  81. ncbi Comparison of warm ischemia versus no ischemia during partial nephrectomy on a solitary kidney
    R Houston Thompson
    Department of Urology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Eur Urol 58:331-6. 2010
    ..The safe duration of warm ischemia during partial nephrectomy (PN) remains controversial...
  82. ncbi Gadolinium enhanced magnetic resonance urography for upper urinary tract malignancy
    Naoki Takahashi
    Department of Radiology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Urol 183:1330-65. 2010
    ..We retrospectively evaluated the accuracy of gadolinium enhanced magnetic resonance urography to detect upper urinary tract tumors...
  83. ncbi Epididymo-orchitis and testicular abscess due to Nocardia asteroides complex
    Jonathan C Routh
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55901, USA
    Urology 65:591. 2005
    ..Sulfa therapy was begun. In previous case reports, this condition carried a 50% mortality rate. Patients who survive seemed to benefit from aggressive surgical debridement and long-term sulfa therapy...
  84. ncbi Percutaneous renal cryoablation: experience treating 115 tumors
    Thomas D Atwell
    Department of Radiology, Mayo Clinic, Rochester, Minnesota 55902, USA
    J Urol 179:2136-40; discussion 2140-1. 2008
    ..We determined technical feasibility, safety and short-term outcomes following percutaneous renal cryoablation...
  85. ncbi Surgical resection of isolated retroperitoneal lymph node recurrence of renal cell carcinoma following nephrectomy
    Stephen A Boorjian
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota, USA
    J Urol 180:99-103; discussion 103. 2008
    ..We report our experience with resection of isolated retroperitoneal lymph node recurrence...
  86. ncbi The role of nephron sparing surgery for metastatic (pM1) renal cell carcinoma
    Amy E Krambeck
    Department of Urology, Mayo Medical School and Mayo Clinic, Rochester, Minnesota 55905, USA
    J Urol 176:1990-5; discussion 1995. 2006
    ..Studies have demonstrated increased time to progression when cytoreductive nephrectomy is performed for metastatic renal cell carcinoma. We evaluated the role of nephron sparing surgery in these patients...
  87. ncbi Outcomes of Gleason score 10 prostate carcinoma treated by radical prostatectomy
    Brant A Inman
    Department of Urology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Urology 68:604-8. 2006
    ..Controversy exists as to which form of therapy is most effective for high-grade prostate cancer (PCa)...
  88. ncbi Adenocarcinoma of the prostate: epidemiological trends, screening, diagnosis, and surgical management of localized disease
    Jonathan C Routh
    Department of Urology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 80:899-907. 2005
    ..In all, this article aims to give the reader a broad overview of the basic elements of prostate cancer diagnosis and surgical treatment in the modem era...
  89. ncbi Impact of Parkinson's disease on continence after radical prostatectomy
    Jonathan C Routh
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55901, USA
    Urology 68:575-7. 2006
    ..Thus, it is possible that men with PD have been denied a potentially curative surgery only on the basis of long-standing assumptions. We addressed this issue by examining a cohort of men with PD who underwent RP at our institution...
  90. ncbi Loss of expression of von Hippel-Lindau tumor suppressor protein associated with improved survival in patients with early-stage clear cell renal cell carcinoma
    Alexander S Parker
    Department of Urology, Mayo Clinic Jacksonville, Jacksonville, Florida 32224, USA
    Urology 65:1090-5. 2005
    ..Recent data have suggested that somatic mutations of the VHL tumor suppressor gene are associated with better cancer-specific survival in patients with CC-RCC...
  91. ncbi Contemporary imaging modalities for the surveillance of patients with renal cell carcinoma
    Matthew K Tollefson
    Department of Urology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Curr Urol Rep 8:38-43. 2007
    ..Herein we review the relevance of these modalities to the follow-up of patients with renal cell carcinoma...
  92. ncbi Percutaneous cryoablation of 40 solid renal tumors with US guidance and CT monitoring: initial experience
    Thomas D Atwell
    Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA
    Radiology 243:276-83. 2007
    ..To retrospectively determine the safety and effectiveness of percutaneous cryoablation, monitored with computed tomography (CT), for the treatment of solid renal masses...
  93. ncbi Percutaneous cryoablation of large renal masses: technical feasibility and short-term outcome
    Thomas D Atwell
    Department of Radiology, Mayo Clinic, 200 1st St SW, Rochester, MN 55902, USA
    AJR Am J Roentgenol 188:1195-200. 2007
    ..This retrospective study was performed to assess the feasibility, safety, and short-term outcome of percutaneous cryoablation of large solid renal tumors...
  94. ncbi TNM T3a renal cell carcinoma: adrenal gland involvement is not the same as renal fat invasion
    Ken-ryu Han
    Deparment of Urology, University of California-Los Angeles School of Medicine, USA
    J Urol 169:899-903; discussion 903-4. 2003
    ..While these data await external validation, consideration should be given to re-categorizing tumors with direct adrenal gland involvement as stage pT4 or in a subcategory such as pT4a...
  95. ncbi Re: Location of extrarenal tumor extension does not impact survival of patients with pT3a renal cell carcinoma. V. Margulis, P. Tamboli, S. F. Matin, M. Meisner, D. A. Swanson and C. G. Wood. J Urol 2007; 178: 1878-1882
    R Houston Thompson
    J Urol 180:409; author reply 409-10. 2008
  96. ncbi Comparison of presentation and outcome for patients 18 to 40 and 60 to 70 years old with solid renal masses
    Michael D Gillett
    Division of Urology, Southern Illinois University, Springfield, Illinois, USA
    J Urol 173:1893-6. 2005
    ..These factors likely contributed to improved cancer specific survival for younger patients...
  97. ncbi Associations with contralateral recurrence following nephrectomy for renal cell carcinoma using a cohort of 2,352 patients
    Ahmad H Bani-Hani
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    J Urol 173:391-4. 2005
    ....
  98. ncbi Surgical resection provides excellent outcomes for patients with cystic clear cell renal cell carcinoma
    W Scott Webster
    Department of Urology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Urology 70:900-4; discussion 904. 2007
    ..However, long-term outcome data are lacking. We reviewed our experience with RCC and report on pathologic features and patient outcome associated with the cystic variant...